MicroPort CardioFlow Medtech Corporation (“CardioFlow Medtech” or “the Company”，2160.HK) is successfully listed on Hong Kong Stock Exchange on February 4th, 2021. The pre-green shoe offering size was US$ 324 million and the post-green shoe offering size is US$372 million (the Offering). CICC acted as the Joint Sponsor and Joint Global Coordinator in this listing. Leveraging its full-spectrum and one-stop financial services, CICC is committed to assisting the clients to achieve their strategic goals.

CardioFlow Medtech is a leading company in the industry and enjoys good reputation in the market. The offering valuation of the Company records the highest among innovative medical device companies on HKEx since 2018.

About CardioFlow Medtech

The Company is a medical device company in China focusing on the research, development and commercialization of innovative transcatheter and surgical solutions for valvular heart diseases. The Company’s mission is to improve the lives of valvular heart disease patients by providing optimal and affordable medical solutions through continuous innovation.

The Company’s self-developed first-generation TAVI (Transcatheter Aortic Valve Implantation) product, VitaFlow^TM, was approved by the NMPA in July 2019 and subsequently commercialized in China in August 2019. According to Frost & Sullivan, VitaFlow^TM is the first one utilizing bovine pericardium as valve tissue. The Company’s second-generation TAVI product, VitaFlow^TM II, has completed the Registration Clinical Trial in China and is also under clinical trial in Europe. In October 2020, the Company submitted the registration application for VitaFlow^TM II to the NMPA, and got accepted. In addition to TAVI products, the Company strategically targets the mitral valve, tricuspid      valve and other emerging markets with high potential, through in-house development and collaboration with the Company’s global partners.

As the Joint Sponsor of the Offering, CICC actively participated in the communication with regulatory authorities and the work of various business lines in the process of spin-off listing on HKEx, ensured the overall progress of the project, provided suggestions and escorted for the project execution. During the issuance, with deep understanding of Hong Kong's capital market and rich experience in IPO project execution, CICC fully tapped the needs of investors, accurately handle the price range, introduced a number of high-quality cornerstone investors, efficiently converted bookkeeping orders, and helped the company achieve high-end pricing and successfully complete the issuance. 

In this IPO, CICC has won high praise and extensive recognition from the client in this deal. As a leading investment bank with “China Roots, International Reach”, CICC will continue to utilize its capital market expertise as well as its seamless cooperation of onshore and offshore businesses to provide continuous support to our customers in terms of introduction of global investors, reaching international capital market, and promoting global business development.